Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 81 clinical trials
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers

Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood

diphosphonates
docetaxel
growth factor
angiogenesis inhibitor
androgen
  • 194 views
  • 29 Oct, 2022
  • 1 location
Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (GUIDE)

how men feel during treatment while still treating the prostate cancer effectively. Docetaxel is a chemotherapy drug that is approved to treat prostate cancer and has been used for many years

  • 0 views
  • 25 Mar, 2022
  • 2 locations
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

positive pancreatic cancer that has spread to other places in the body (advanced). Anetumab ravtansine is a monoclonal antibody, called anetumab ravtansine, linked to a chemotherapy drug called DM4

gemcitabine
chemotherapy drug
inhibition of ovulation
glomerular filtration rate
progesterone
  • 153 views
  • 21 Oct, 2022
  • 20 locations
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive

  • 0 views
  • 13 Oct, 2022
  • 1 location
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-positive cancer cells in a targeted way and delivers ozogamicin to kill them. Giving

allogeneic bone marrow transplantation
bone marrow procedure
chemotherapy drug
filgrastim
leukemia
  • 2 views
  • 21 Apr, 2022
  • 1 location
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

cancer cells. Cyclophosphamide is chemotherapy drug that is approved for the treatment of various cancers alone and in combination with other drugs.

lung cancer
chemotherapy drug
carcinoma
line of therapy
interval debulking surgery
  • 57 views
  • 03 Mar, 2022
  • 1 location
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

would be leukemia cells). The drug is then internalized and the chemotherapy drug becomes activated. Gemtuzumab is currently FDA approved for the treatment of acute myeloid leukemia. The

hla-a
leukapheresis
fludarabine
cancer
refractory acute myeloid leukemia (aml)
  • 3 views
  • 15 May, 2022
  • 1 location
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab

human epidermal growth factor
serum total bilirubin
triple negative breast cancer
carcinoma
growth factor
  • 27 views
  • 17 Jun, 2022
  • 4 locations
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

may allow chemotherapy to kill the cells more easily. Researchers want to see how well it works with temozolomide, a chemotherapy drug that is designed to damage tumor cell DNA. These drugs will be

mitomycin
solid tumour
cancer
neutrophil count
secondary malignant neoplasm of liver
  • 13 views
  • 04 Oct, 2022
  • 1 location
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and severity of GVHD. Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side

hematologic malignancy
sirolimus
mycophenolate mofetil
allogeneic transplantation
granulocyte colony stimulating factor
  • 0 views
  • 25 Oct, 2022
  • 2 locations